A subscription to JoVE is required to view this content. Sign in or start your free trial.

Research Article

Network Pharmacology and Experimental Research of β-Sitosterol in Treating Chronic Obstructive Pulmonary Disease via the Glucocorticoid Receptor

104 views

DOI:

10.3791/72018

August 7th, 2026

* These authors contributed equally

In This Article

Summary

β-sitosterol alleviated COPD and potentiated the efficacy of dexamethasone, with the glucocorticoid receptor mediating this effect. Additionally, β-sitosterol reduced inflammation, oxidative stress, and cellular senescence in both CSE-stimulated bronchial epithelial cells and cigarette smoke-induced COPD mice.

Abstract

Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory disorder characterized by persistent inflammation, oxidative stress, and progressive lung function decline. The therapeutic potential of β-sitosterol in COPD remains unclear. This study aimed to investigate the protective effects of β-sitosterol against COPD and elucidate its underlying mechanism. Database screening identified the glucocorticoid receptor (GR) as a potential target of β-sitosterol. A cigarette smoke-induced COPD mouse model and a cigarette smoke extract (CSE)-stimulated BEAS-2B cell model were established. Pulmonary function, lung injury-related markers, inflammation, oxidative stress, and cellular senescence were assessed using (RT-qPCR), DCFH-DA fluorescent probe assays, and senescence detection kits. The effects of β-sitosterol alone or in combination with dexamethasone (DEX) were also evaluated. β-sitosterol significantly improved pulmonary function, normalized lung injury-related markers, and attenuated inflammation, oxidative stress, and cellular senescence in both CSE-stimulated BEAS-2B cells and cigarette smoke-exposed mice. These protective effects were accompanied by increased GR expression. Moreover, β-sitosterol enhanced responsiveness to DEX, and combined treatment with β-sitosterol and DEX produced greater improvements in pulmonary function, lung injury markers, inflammation, reactive oxygen species levels, and cellular senescence than DEX treatment alone. Collectively, these findings suggest that β-sitosterol alleviates COPD-associated pathological changes, at least in part, by upregulating GR expression and enhancing the therapeutic efficacy of DEX, highlighting its potential as an adjuvant strategy for COPD treatment.

Introduction

Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disease characterized by persistent airway inflammation, alveolar damage, and irreversible airflow obstruction that impairs respiratory function and reduces quality of life1. Its prevalence increases significantly with age, and the risk for people aged sixty-five and over is about five times that of people under forty2. This demographic trend is associated with increased disease incidence, mortality, and disability3. Epidemiological projections indicate that by 2030, COPD may become the fourth leading cause of death worldwide, accounting for about 5% of all deaths4,5,6. At present, the identified risk factors include genetic susceptibility, pulmonary dysplasia, particulate matter exposure, chronic bronchitis, and respiratory infection7.

Among the risk factors, cigarette smoke is the most important pathogenic factor of COPD8. It contains thousands of chemicals that can cause bronchial epithelial damage, promote the infiltration of inflammatory cells, and lead to remodeling of lung tissue9. Long-term exposure can induce persistent and irreversible epithelial injury, promote the release of a large number of pro-inflammatory chemokines, significantly increase (ROS) production, and induce cell apoptosis10. Many studies have shown that the increased levels of pro‑inflammatory chemokines such as interleukin‑8 (IL-8) and tumor necrosis factor‑α (TNF‑α), together with excessive ROS production and cellular senescence, are closely related to the severity of COPD11,12. This highlights the need for agents that can effectively and safely modulate these key pathogenic factors to exert protective and therapeutic effects in COPD.

Phytosterols are natural bioactive compounds ubiquitously present in plant cell membranes. Among them, β‑sitosterol is the most abundant and is widely distributed in lipid‑rich plant‑derived foods such as vegetables, nuts, seeds, and olive oil13,14,15,16. Studies have confirmed that administration of β‑sitosterol at doses up to 1000 mg/kg in rats and mice is not associated with cytotoxicity or genotoxicity17. Moreover, research has shown that β‑sitosterol exhibits antioxidant properties through its effects on antioxidant enzymes and human estrogen receptors18.

β‑sitosterol displays a broad spectrum of pharmacological activities, including anti‑inflammatory19, antipyretic20, analgesic21, and antidiabetic effects13. It has also shown therapeutic potential in various disease models, such as colitis and intestinal inflammation22, and possesses anti‑atherosclerotic23 and immunomodulatory properties24. Additionally, it has a favorable safety profile. Given these characteristics, β‑sitosterol has attracted considerable interest as a potential drug candidate. However, its precise role and underlying mechanisms in COPD remain largely unclear.

Therefore, the present study aimed to investigate the potential therapeutic effects and underlying mechanisms of β‑sitosterol in COPD. Specifically, a cigarette smoke extract (CSE)‑induced BEAS‑2B cell injury model was used to evaluate whether β‑sitosterol could effectively alleviate CSE‑mediated cellular damage, thereby identifying a novel candidate molecule for COPD therapeutic strategies.

Access restricted. Please log in or start a trial to view this content.

Protocol

The study was conducted in accordance with the Basic & Clinical Pharmacology & Toxicology guidelines for experimental and clinical studies25. All animal experimental protocols were approved by the Animal Ethics Committee of The Second Affiliated Hospital, Zhejiang University School of Medicine (Approval No. 20230102), and all experiments were performed in accordance with the guidelines of the Animal Ethics Committee. The study was conducted in agreement with the ARRIVE guidelines.

Screening of key components and targets via network pharmacology

Active components of Fritillaria cirrhosa D. Don, Lonicera japonica Thunb., Glehnia littoralis F. Schmidt ex Miq., and Adenophora stricta Miq. were retrieved from the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP; accessed 12 March 2024). Candidate compounds were screened according to the following ADME criteria: oral bioavailability (OB) ≥ 30%, drug-likeness (DL) ≥ 0.18, and Caco-2 permeability ≥ −0.425. Compounds meeting all three criteria were retained as candidate active ingredients for subsequent analyses.

The canonical Simplified Molecular Input Line Entry System (SMILES) structure of β-sitosterol was obtained from PubChem (accessed 18 March 2024) and imported into SwissTargetPrediction (accessed 21 March 2024) for target prediction. Homo sapiens was selected as the target species. Potential targets were predicted based on 2D and 3D structural similarity between β-sitosterol and known ligands in the database. Predicted targets with a probability greater than 0 were retained, and duplicate entries were removed.

COPD-associated genes were retrieved from the Therapeutic Target Database (TTD; accessed 25 March 2024) and the Comparative Toxicogenomics Database (CTD; accessed 28 March 2024) using the keyword “chronic obstructive pulmonary disease”. After removal of duplicate genes, the COPD-associated genes were intersected with the predicted β-sitosterol targets to identify candidate targets potentially involved in the therapeutic effects of β-sitosterol against COPD.

Molecular docking of β‑sitosterol and GR

The three-dimensional structure of β-sitosterol in SDF format was retrieved from the PubChem database (accessed 2 June 2026), while the crystal structure of the glucocorticoid receptor (GR) was obtained from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB; accessed 3 June 2026). After standard preparation of the ligand and receptor structures, molecular docking was performed using the CB-Dock2 online platform (accessed 3 June 2026). The prepared ligand and receptor files were uploaded to the platform, and docking calculations were conducted using the default parameters.

Functional enrichment analysis of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG)

All predicted target genes of β-sitosterol were subjected to GO functional enrichment and KEGG pathway enrichment analyses. Enrichment outcomes, including significantly enriched biological processes, cellular components, molecular functions, and signaling pathways, were sorted and stored in Supplementary File 1 for subsequent bioinformatic analysis.

Animal modeling and grouping

The sample size was set at six animals per group based on a previous study that performed an a priori power analysis using G*Power software (α = 0.05, power = 0.80) and demonstrated that n = 6 was sufficient to detect biologically relevant differences under comparable experimental conditions26. Male C57BL/6 mice aged 6–8 weeks (20 ± 2 g) were randomly assigned to five groups: control group, COPD model group, COPD + dexamethasone (DEX) group, COPD + β-sitosterol group, and COPD + DEX + β-sitosterol group. Mice were housed under standard laboratory conditions (25 °C, 12 h light/dark cycle) with free access to standard chow and water and were allowed to acclimatize for 1 week before experimentation.

For COPD model establishment, mice were placed in a whole-body cigarette smoke exposure chamber (63 cm × 55 cm × 45 cm) and exposed to mainstream cigarette smoke for 12 weeks. Each cigarette contained 10 mg tar, 0.9 mg nicotine, and 10 mg carbon monoxide. Smoke exposure was conducted twice daily (5 days/week) at 9:30 a.m. and 3:00 p.m., with smoke generated from 18 cigarettes delivered into the chamber for 90 min per session27.

To evaluate the therapeutic effects of the interventions, drug administration was initiated after 8 weeks of cigarette smoke exposure and continued for the remaining 4 weeks. Beginning at week 9, mice in the respective treatment groups received daily intragastric administration of DEX (1 mg/kg)28 or β-sitosterol (50 mg/kg)29,30 1 h before cigarette smoke exposure. Previous pharmacokinetic studies have reported an oral bioavailability of approximately 4% for β-sitosterol in rodents31. In addition, several mouse studies have employed doses ranging from 20 to 50 mg/kg32. Therefore, a dose of 50 mg/kg was selected to ensure adequate systemic exposure while remaining within the range commonly used in preclinical studies.

Mice in the control group were exposed to filtered room air, whereas mice in the model and treatment groups received an equivalent volume of normal saline as a vehicle. At the end of the experimental period, mice were deeply anesthetized with isoflurane until loss of pedal reflex and euthanized by exsanguination via abdominal aorta blood collection. The thoracic cavity was immediately opened, and intact bilateral lung tissues were carefully excised, rinsed with ice-cold phosphate-buffered saline (PBS), and placed on ice. For bronchoalveolar lavage fluid (BALF) collection, the trachea was cannulated and lavaged with cold sterile PBS, which was gently instilled and withdrawn repeatedly to collect lavage fluid. Lung tissues and BALF samples were maintained on ice and subsequently processed for downstream analyses.

BEAS‑2B cell culture

BEAS-2B human bronchial epithelial cells were maintained in Dulbecco's Modified Eagle Medium/F12 (DMEM/F12) containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin under 5% CO₂ at 37 °C.

CSE preparation and BEAS‑2B cell exposure

BEAS‑2B cells were washed with phosphate-buffered saline and seeded into 24‑well plates in triplicate at a density of 5 × 104 cells per well. After 12 h of culture, cells reached approximately 60% confluency and were then exposed to CSE. CSE was prepared freshly as previously described, with minor modifications33. Briefly, one unfiltered commercial cigarette was continuously combusted, and mainstream smoke was bubbled into 10 mL of serum‑free medium using a vacuum pump at a constant flow rate of 1.05 L/min (approximately −11 kPa negative pressure) for approximately 5 min until the cigarette was completely burned. The obtained solution was first subjected to pre-filtration to remove large particulate impurities, then sterilized via a 0.22 µm sterile microporous filter to eliminate residual particles; the resultant stock solution was defined as 100% CSE. All freshly prepared CSE was used for cell treatment immediately after filtration without storage. Cells were stimulated with medium containing 2.5% CSE. After 24 h of CSE treatment, the culture supernatants were collected and stored at -40 °C for subsequent analysis34.

Quantitative real-time polymerase chain reaction (RT‑qPCR)

Total RNA was extracted from BEAS-2B cells using a total RNA extraction kit and reverse-transcribed into cDNA using a reverse transcription kit according to the manufacturers’ instructions. RT-qPCR was subsequently performed using a real-time PCR detection system and a SYBR Green-based qPCR master mix. All RT-qPCR experiments were conducted with three biological replicates and three technical replicates per sample to ensure data reliability.

Each qPCR reaction was performed in a total volume of 20 µL, containing 10 µL of SYBR Green qPCR master mix, 0.4 µL of forward primer, 0.4 µL of reverse primer, 2 µL of diluted cDNA template, and 7.2 µL of RNase-free water. The amplification conditions were as follows: initial denaturation at 95 °C for 3 min, followed by 40 cycles of denaturation at 95 °C for 10 s and annealing/extension at 60 °C for 30 s. Relative gene expression levels were calculated using the 2−ΔΔCt method, with GAPDH serving as the internal reference gene. The primer sequences used in this study are mentioned in Supplementary Table 1.

Intracellular reactive oxygen species (ROS) analysis

Intracellular ROS production in BEAS-2B cells was assessed using the fluorogenic probe 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) and analyzed by flow cytometry. During flow cytometric acquisition, a standard forward scatter (FSC) and side scatter (SSC) gating strategy was applied to exclude cellular debris and select intact single cells. A total of 10,000 valid cellular events were acquired for each sample. The excitation and emission wavelengths were set at 488 nm and 525 nm, respectively. Flow cytometric data were subsequently analyzed to quantify intracellular ROS fluorescence intensity.

Malondialdehyde (MDA) level determination

Intracellular MDA content was measured using a lipid peroxidation assay kit according to the manufacturer's instructions. Briefly, treated BEAS-2B cells were harvested and lysed, then centrifuged at low temperature to collect the supernatant. The thiobarbituric acid (TBA) colorimetric reaction was then performed, and absorbance was measured at 532 nm using a microplate reader. Relative MDA levels were calculated according to the standard curve.

Cell senescence assessment

Cellular senescence was evaluated using a senescence detection assay based on senescence-associated β-galactosidase (SA-β-gal) activity. SA-β-gal-positive cells were quantified by flow cytometry. In parallel, the mRNA expression levels of the senescence-associated markers p53 and p21 were determined by RT-qPCR.

Cell proliferation assay

Cell proliferation was assessed using a colorimetric cell viability assay kit. Absorbance was measured at 450 nm using a microplate reader.

GR knockdown assay

Cell transfection was performed using a lipid-based transfection reagent. The following oligonucleotides were transfected: glucocorticoid receptor-targeting small interfering RNA (si-GR) and negative control small interfering RNA (si-NC). Candidate siRNA sequences targeting GR were designed using the online bioinformatics platform siDirect 2.0. Following transfection, cells were cultured for 48 h, and all siRNAs were used at a final concentration of 50 nM. Knockdown efficiency was verified by measuring GR mRNA expression using RT-qPCR.

Vehicle control groups were included in both β-sitosterol treatment and transfection experiments. For β-sitosterol intervention, cells treated with vehicle solvent alone served as the vehicle control group (denoted as CSE+0). Statistical analysis confirmed that no significant differences were observed between the vehicle control and blank control groups.

Statistical analysis

All quantitative results were expressed as mean ± standard deviation from three biologically independent in vitro experiments. Statistical analyses were performed using statistical analysis software. The Shapiro–Wilk test was used to examine the normality of the dataset distribution prior to statistical testing; Bonferroni post-hoc correction was adopted to adjust P values for multiple comparisons after analysis of variance (ANOVA). Comparisons between two groups were assessed by an unpaired Student's t-test, while one‑way or two‑way ANOVA was employed for multi‑group comparisons. A p‑value ≤ 0.05 was considered statistically significant.

Access restricted. Please log in or start a trial to view this content.

Results

β-sitosterol was a potential natural product for treating COPD

Due to the reported curative effects of Fritillaria cirrhosa D. Don, dried flower of Lonicera japonica Thunb., dried root of Glehnia littoralis F. Schmidt ex Miq., and Adenophora stricta Miq. in treating pulmonary diseases35,36,37,38, this study used th...

Access restricted. Please log in or start a trial to view this content.

Discussion

COPD imposes a substantial global disease burden and remains a major challenge to worldwide health1. Current management of COPD encompasses both pharmacological and non‑pharmacological interventions42. Among pharmacological treatments, glucocorticosteroids (GCs) are widely used in chronic inflammatory disorders. They act by binding to the GR and recruiting histone deacetylase 2 into transcriptional complexes to reverse histone acetylation43. Ho...

Access restricted. Please log in or start a trial to view this content.

Disclosures

The Author(s) declare(s) that there is no conflict of interest.

Acknowledgements

The authors have no acknowledgments.

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
BEAS-2B human bronchial epithelial cellsSunnCell, ChinaSC-0218Human bronchial epithelial cell line for in vitro study
C57BL/6 miceVital River Laboratories, China213Animal model for COPD in vivo experiment
CB-DOCK2Chinahttps://cadd.labshare.cn/cb-dock2/php/index.phpfor molecular docking simulation between ligand and receptor protein
Cell Counting Kit-8 (CCK-8)Beyotime Biotechnology, ChinaC0038Detection of cell viability and proliferation
CellEvent™ Senescence Green Detection KitThermo Fisher, USAC10851Detection of cellular senescence
CigarettesHongta, ChinaNot providedCigarette used for smoke exposure and CSE preparation
CTDUSAhttps://ctdbase.org/for retrieving COPD-related genes
DCFH-DA fluorescent probeSigma-Aldrich, USAD6883-50MGDetection of intracellular ROS level
Dexamethasone (DEX)Yeasen, China40323ES03Glucocorticoid for combined intervention
DMEM/F12 mediumGibco, USA11330032Basal medium for BEAS-2B cell culture
Fetal bovine serum (FBS)Gibco, USA10270106Supplement for cell culture medium
GraphPad Prism GraphPad Software, USA9.3.1Data statistical analysis and graph drawing
IsofluraneRWD Life Science, ChinaR510-22-10Inhaled anesthetic for animal euthanasia
Lipid Peroxidation MDA Assay KitBeyotime Biotechnology, ChinaS0131SDetection of intracellular malondialdehyde (MDA) content
Lipofectamine 2000Thermo Fisher, USA11668030Transfection reagent for siRNA delivery
Multimode microplate readerThermo Fisher, USAVL0000D0Detection of absorbance and fluorescence value
Navios EX Flow CytometerBeckman Coulter, USAB80912Analysis of ROS and senescent cells
Penicillin/streptomycinHyClone, USASV30010Antibiotics to prevent bacterial contamination
Power SYBR™ Green Master MixThermo Fisher, USA4367659Fluorescent quantitative PCR amplification
PrimeScript™ RT reagent KitTakara, JapanRR037QReverse transcription for cDNA synthesis
PubChem databaseUSAhttps://pubchem.ncbi.nlm.nih.gov/for acquiring canonical SMILES sequence and downloading 3D SDF structural information of beta-sitosterol
QuantStudio Dx PCR InstrumentThermo Fisher, USA4479889Real-time RT-qPCR detection
RCSB PDBUSAhttps://www.rcsb.org/to obtain GR crystal 3D structure file
RNA/Protein Isolation KitBeyotime Biotechnology, ChinaR0018STotal RNA extraction from cell and lung tissue
si-GRDesigned in silico via siDirect 2.1Custom synthesisGuide: 5′-UUUUGAAUGGGUGUAGCAA-3′; Passenger: 5′-GCUUUCACCCAUUCAAAAGG-3′, knockdown for GR
si-NCThermo Fisher, USA4390843used as negative transfection control for cellular and in vivo assays
SwissTargetPrediction databaseSwitzerlandhttp://swisstargetprediction.ch/for in silico prediction of potential drug-related protein targets
TCMSP databaseChinahttps://www.tcmsp-e.com/for herbal ingredient screening and target prediction
TTDSingaporehttps://db.idrblab.net/ttd/for collection of validated COPD-associated disease genes
Whole-body smoke exposure chamberTeague Enterprise, USATE-2Establishment of cigarette smoke-induced COPD model
β-sitosterolChemicalBook, China83-46-5Active phytosterol for drug treatment

References

  1. Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet. 2022;10342:2227-2242.
  2. Raherison C, Girodet PO. Epidemiology of COPD. Eur Respir Rev. 2009;114:213-221.
  3. Kennedy BK et al. Geroscience: linking aging to chronic disease. Cell. 2014;4:709-713.
  4. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;11:e442.
  5. Hanania NA, Marciniuk DD. A unified front against COPD: clinical practice guidelines from the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European Respiratory Society. Chest. 2011;3:565-566.
  6. Rabe KF et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;6:532-555.
  7. Szalontai K et al. Chronic obstructive pulmonary disease: Epidemiology, biomarkers, and paving the way to lung cancer. J Clin Med. 2021;13: 2889.
  8. Chen J et al. DNA of neutrophil extracellular traps promote NF-kappaB-dependent autoimmunity via cGAS/TLR9 in chronic obstructive pulmonary disease. Signal Transduct Target Ther. 2024;1:163.
  9. Vij N et al. Cigarette smoke-induced autophagy impairment accelerates lung aging, COPD-emphysema exacerbations and pathogenesis. Am J Physiol Cell Physiol. 2018;1:C73-C87.
  10. Zhu X et al. Cigarette smoke promotes interleukin-8 production in alveolar macrophages through the reactive oxygen species/stromal interaction molecule 1/Ca(2+) Axis. Front Physiol. 2021;12:733650.
  11. Cheng M et al. Qingke Pingchuan granules alleviate airway inflammation in COPD exacerbation by inhibiting neutrophil extracellular traps in mice. Phytomedicine. 2025;136:156283.
  12. Hikichi M, Mizumura K, Maruoka S, Gon Y. Pathogenesis of chronic obstructive pulmonary disease (COPD) induced by cigarette smoke. J Thorac Dis. 2019;Suppl 17:S2129-S2140.
  13. Babu S, Jayaraman S. An update on beta-sitosterol: A potential herbal nutraceutical for diabetic management. Biomed Pharmacother. 2020;131:110702.
  14. Cheng Y et al. Dietary beta-sitosterol regulates serum lipid level and improves immune function, antioxidant status, and intestinal morphology in broilers. Poult Sci. 2020;3:1400-1408.
  15. Takayasu BS et al. Biological effects of an oxyphytosterol generated by beta-Sitosterol ozonization. Arch Biochem Biophys. 2020;696:108654.
  16. Awad AB, Chinnam M, Fink CS, Bradford PG. Beta-sitosterol activates Fas signaling in human breast cancer cells. Phytomedicine. 2007;11:747-754.
  17. Paniagua-Perez R et al. Genotoxic and cytotoxic studies of beta-sitosterol and pteropodine in mouse. J Biomed Biotechnol. 2005;3:242-247.
  18. Moreno JJ, Mitjavila MT. The degree of unsaturation of dietary fatty acids and the development of atherosclerosis (review). J Nutr Biochem. 2003;4:182-195.
  19. Liao PC et al. Identification of beta-Sitosterol as in vitro anti-inflammatory constituent in Moringa oleifera. J Agric Food Chem. 2018;41:10748-10759.
  20. Gupta MB et al. Anti-inflammatory and antipyretic activities of beta-sitosterol. Planta Med. 1980;2:157-163.
  21. Nirmal SA, Pal SC, Mandal SC, Patil AN. Analgesic and anti-inflammatory activity of beta-sitosterol isolated from Nyctanthes arbortristis leaves. Inflammopharmacology. 2012;4:219-224.
  22. Kim KA et al. Beta-Sitosterol attenuates high-fat diet-induced intestinal inflammation in mice by inhibiting the binding of lipopolysaccharide to toll-like receptor 4 in the NF-kappaB pathway. Mol Nutr Food Res. 2014;5:963-972.
  23. Tada H et al. Sitosterolemia, Hypercholesterolemia, and Coronary Artery Disease. J Atheroscler Thromb. 2018;9:783-789.
  24. Efsa Panel on Nutrition NF, Food A et al. A combination of beta-sitosterol and beta-sitosterol glucoside and normal function of the immune system: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA J. 2019;7:e05776.
  25. Huang J et al. Identification of the active compounds and significant pathways of yinchenhao decoction based on network pharmacology. Mol Med Rep. 2017;4:4583-4592.
  26. Ashok V et al. Evaluation of 3D-printed polylactic acid as a bone substitute: An animal study in a rat model. Clin Exp Dent Res. 2025;4:e70201.
  27. Zhang R et al. Soyasaponin I alleviates inflammation and oxidative stress in chronic obstructive pulmonary disease through inhibiting the mitogen-activated protein kinase (MAPK) signaling pathway. Exp Anim. 2025;4:407-418.
  28. Liu R et al. Therapeutic effects of Hedyotis diffusa Willd in a COPD mouse model challenged with LPS and smoke. Exp Ther Med. 2018;4:3385-3391.
  29. Baraya YS, Yankuzo HM, Wong KK, Yaacob NS. Strobilanthes crispus bioactive subfraction inhibits tumor progression and improves hematological and morphological parameters in mouse mammary carcinoma model. J Ethnopharmacol. 2021;267:113522.
  30. Tang X et al. Treatment with beta-sitosterol ameliorates the effects of cerebral ischemia/reperfusion injury by suppressing cholesterol overload, endoplasmic reticulum stress, and apoptosis. Neural Regen Res. 2024;3:642-649.
  31. Sylven C, Borgstrom B. Absorption and lymphatic transport of cholesterol and sitosterol in the rat. J Lipid Res. 1969;2:179-182.
  32. Jayaraman S et al. Beta-Sitosterol circumvents obesity induced inflammation and insulin resistance by down-regulating IKKbeta/NF-kappaB and JNK signaling pathway in adipocytes of type 2 diabetic rats. Molecules. 2021;7:2101.
  33. Higashi T et al. A simple and rapid method for standard preparation of gas phase extract of cigarette smoke. PLoS One. 2014;9:e107856.
  34. Carvalho JL et al. Oral feeding with probiotic Lactobacillus rhamnosus attenuates cigarette smoke-induced COPD in C57Bl/6 mice: Relevance to inflammatory markers in human bronchial epithelial cells. PLoS One. 2020;4:e0225560.
  35. Li L et al. Fritillaria cirrhosa D. Don Alleviates Inflammatory Progression and Suppresses M1 Polarization of Macrophages in Chronic Obstructive Pulmonary Disease. Int Arch Allergy Immunol. 2025;3:243-251.
  36. Xiong L et al. The protective effect of Lonicera japonica Thunb. against lipopolysaccharide-induced acute lung injury in mice: Modulation of inflammation, oxidative stress, and ferroptosis. J Ethnopharmacol. 2024;331:118333.
  37. Park SM et al. Adenophora stricta Root Extract Protects Lung Injury from Exposure to Particulate Matter 2.5 in Mice. Antioxidants (Basel). 2022;7:1376.
  38. Park J et al. Cytotoxic activity of C(17) polyacetylenes from the roots of Glehnia littoralis against drug-resistant colorectal and lung cancer cells. J Nat Med. 2025;2:391-398.
  39. Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;3:636-645.
  40. Aviles B et al. Markers of airway remodeling in induced sputum from healthy smokers. Arch Bronconeumol. 2006;5:235-240.
  41. Chen Q et al. Resveratrol inhibits lipopolysaccharide‑induced MUC5AC expression and airway inflammation via MAPK and Nrf2 pathways in human bronchial epithelial cells and an acute inflammatory mouse model. Mol Med Rep. 2025;6:157.
  42. Singh D, Higham A, Mathioudakis AG, Beech A. Chronic obstructive pulmonary disease (COPD): Developments in pharmacological treatments. Drugs. 2025;7:911-930.
  43. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med. 2005;16:1711-1723.
  44. Morjaria JB, Malerba M, Polosa R. Biologic and pharmacologic therapies in clinical development for the inflammatory response in COPD. Drug Discov Today. 2010;9-10:396-405.
  45. Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol. 2006;3:245-254.
  46. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet. 2009;9678:1905-1917.
  47. Shen HF et al. MiR-361-5p/abca1 and MiR-196-5p/arhgef12 axis involved in gamma-Sitosterol inducing dual anti-proliferative effects on bronchial epithelial cells of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2021;16:2741-2753.
  48. Sun Y, Gao L, Hou W, Wu J. Beta-sitosterol alleviates inflammatory response via inhibiting the activation of ERK/p38 and NF-kappaB pathways in LPS-exposed BV2 cells. Biomed Res Int. 2020;2020:7532306.
  49. Adcock IM, Mumby S. Glucocorticoids. Handb Exp Pharmacol. 2017;237:171-196.
  50. Reddy AT, Lakshmi SP, Banno A, Reddy RC. Glucocorticoid receptor alpha mediates Roflumilast's ability to restore dexamethasone sensitivity in COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:125-134.
  51. Kadushkin AG et al. The effect of glucocorticoids in combination with azithromycin or theophylline on cytokine production by NK and NKT-like blood cells of patients with chronic obstructive pulmonary disease. Biomed Khim. 2021;4:352-359.
  52. Zhou L et al. Expression of glucocorticoid receptor and HDACs in airway smooth muscle cells is associated with response to steroids in COPD. Respir Res. 2024;1:227.

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

Beta SitosterolPulmonary FunctionOxidative StressCellular SenescenceCigarette Smoke ModelBEAS 2B CellsDexamethasone TreatmentInflammation Markers